Teva to lose grip on Copaxone next year
20-11-2013
On January 28, Teva announced that the US Food and Drug Administration (FDA) had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Copaxone, Teva, FDA, dosage, dosage patent
